title: Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.
abstract: Sodium-glucose linked transporter 2 inhibitors limit the reabsorption of glucose from glomerular filtrate in the kidneys, reducing blood glucose levels in patients with type- 2 diabetes. This article is meant to evaluate this class of medications for clinicians.
authors.forename: Juan F
authors.initials: JF
authors.lastname: Mosley
authors.forename: Lillian
authors.initials: L
authors.lastname: Smith
authors.forename: Emily
authors.initials: E
authors.lastname: Everton
authors.forename: Chris
authors.initials: C
authors.lastname: Fellner
keywords: canagliflozin; dapagliflozin; empagliflozin; sodium-glucose linked transporter 2 (SGLT2) inhibitors; type-2 diabetes mellitus (T2DM)